Do actuaries believe in longevity deceleration?

Edouard Debonneuil(*), Frédéric Planchet, Stéphane Loisel
ISFA, Longevity 11, 2015
(*) edebonneuil@yahoo.fr

Do actuaries believe in longevity deceleration? Longevity 11, ISFA 2015
Do actuaries believe in longevity deceleration?

- Part I. Extrapolation of the past
- Part II. Taking a prudent view
Modeling a neutral view

In the absence of belief of whether life expectancy increase faster in the future (e.g. biomedical discoveries) or not (e.g. pollution)

EXAMPLE OF BELIEF

Youth pill

Virus

would you, for a central longevity scenario, rather consider **same/lower/higher** mortality improvements than in the past?

\[ i_{x,t} = \frac{q_{x,t+1} - q_{x,t}}{q_{x,t}} \]

Do actuaries believe in longevity deceleration? Longevity 11, ISFA 2015
Historical evolutions of life expectancy

• « +1 quarter per year »

• Piecewise lines

In a central scenario, and in the absence of country-specific context, should life expectancy rather increase by +{20-25}% year per year? less? more?


Do actuaries believe in longevity deceleration? Longevity 11, ISFA 2015
Lee Carter uses the same mortality improvements for the future as in the past; does it lead to $+23\%$ per year?

Extract from the original paper:
“While many methods assume an upper limit to the human life span (...) our method allows (...) the deceleration of life expectancy (...) without any special additional assumptions.”

Hmm... What about the models we use internally?... And the risk scenarios...
Indeed, Using the same mortality improvements for the future than in the past leads to life expectancy deceleration when improvements decrease by age.
Model for a comparison: a simple logistic regression extrapolates life expectancy linearly


Application:

Same pace as in the past
+20% per year: ‘Best Practice trend’:

\[
\text{logit } m_{x,t} = A + B x + C t
\]

\[
\text{logit } m_{x,t} = A + B (x + 20\% t)
\]

‘A’ is adjusted to last years of data, similarly to the level of kappas

\[ \text{kappa of Lee Carter} \quad \text{life expectancy} \]

Do actuaries believe in longevity deceleration? Longevity 11, ISFA 2015
Lee Carter, Best Practice Trend, and... commonly used actuarial tables worldwide. Do actuaries believe in longevity deceleration?

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Canada</td>
<td>Males</td>
<td>e20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chile</td>
<td>Males</td>
<td>e20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>France</td>
<td>Males</td>
<td>e20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Germany</td>
<td>Males</td>
<td>e20</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Do actuaries believe in longevity deceleration? Longevity 11, ISFA 2015
Lee Carter, Best Practice Trend, and… commonly used actuarial tables worldwide. Do actuaries believe in longevity deceleration?
Do actuaries believe in longevity deceleration?

- Part I. Extrapolation of the past
- Part II. Taking a prudent view
What views? What would be a prudent table?

Life Extension Velocity (mortality improvements of 5% at late ages, starting in 2040)

+33% per year (Such happened to best practice life expectancy during 7 decades after Louis Pasteur’s work)

Seen in the previous cases (in the case of French table, the late deceleration comes from a specific closure and does not impact $\bar{a}_x$)

Flat or decreasing life expectancy (Lifestyles and obesity, crisis, war, pollution, virus…)

Is any view ‘NUTS’? /misbalanced? Especially the views at the top, that could challenge retirement systems?
How serious is biogerontology about life extension?

Do these people believe in longevity deceleration? …

• Mortality rates by age tell you that tackling aging is key
• Long-lived mice made 50% and 70% longer lived
  – Same mutation as some human populations that seem immune to diabetes and cancer (Larron dwarfs)
• Some wonder-drugs in our armamentarium?
  – Mice live longer under low doses of aspirin, metformin, rapamycin and others. Similar results are empirically found in humans: data and clinical trials. Knowledge on lifespan will take decades
  – Give your dog rapamycin or placebo! http://dogagingproject.com/join-us/
• Companies now propose you more fundamental treatments
  – BioViva’s human longevity gene therapy in Mexico and Columbia, with worldwide specialist George Curch: one injection for muscles, reduced atherosclerosis, increased telomeres…
  – Intervene Immune grows a brand new thymus in you, to restore your immune system
  – Organovo prints new organs to replace your most damaged ones (for now simple organs)
• Big data and pharmaceutical industries chime in
  – Google/Alphabet’s Calico and Life Sciences
  – Partners: Abbvie, Novartis, Sanofi, etc.
  – Human Longevity, Inc. By Craig Venter
  – Others like InSilico Medicine

Do actuaries believe in longevity deceleration? Longevity 11, ISFA 2015
What potential financial impacts?

Estimated impact on reserves of immediate annuities for a French male aged 65 when changing trends (different from impact on future results; e.g. due to amortization mechanisms) (discount rate of 2%)

<table>
<thead>
<tr>
<th>Year</th>
<th>+4.3%</th>
<th>+13.6%</th>
</tr>
</thead>
<tbody>
<tr>
<td>In 2015</td>
<td></td>
<td></td>
</tr>
<tr>
<td>In 2025</td>
<td>+3.6%</td>
<td>+7.7%</td>
</tr>
<tr>
<td></td>
<td>+1.9%</td>
<td>+4.0%</td>
</tr>
<tr>
<td></td>
<td>+0.6%</td>
<td>+0.7%</td>
</tr>
<tr>
<td>-8.0%</td>
<td>-8.1%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>-18.7%</td>
<td>-19.5%</td>
</tr>
</tbody>
</table>

Such scenarios may be useful to evaluate potential solutions for retirement systems in case large medical improvements were to reach populations soon.

Reminder: the late deceleration of French tables does not affect annuity valuations.
Conclusion

Does it mean anything for retirement systems

- **Non-decelerating central** longevity scenarios could be considered
  - Such as simple logistic regressions…
- Using accelerating longevity scenarios may be good to estimate risks and **risk mitigating solutions**
  - Such as:
  - Preemptively increasing retirement age?
  - **Hedging** longevity risk by investing in
    - Insurance Mortality risk?
    - Businesses that gain with longer lives? Travels, pharmaceuticals, ear adapters…
    - Paradoxically, businesses that attempt to extend lifespan? Using their results to finance retirement.
Do actuaries believe in longevity deceleration?
Edouard Debonneuil(†), Frédéric Planchet, Stéphane Loisel
(†) edebonneuil@yahoo.fr

• Bernardes de Jesus B, Vera E, Schneeberger K, Tejera AM, Ayuso E, Bosch F, Blasco MA. (2012): Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer. EMBO Mol Med. 4:691-704
• Bulterijs S, Hull RS, Bjork VC and Roy AG (2015): It is time to classify biological aging as a disease. Front Genet 6, 205
• Coeurnelle D (2013): Et si on arrêtait de vieillir! : Réalité, enjeux et perspectives d’une vie en bonne santé beaucoup plus longue. Editions FYP
• Gems D (2014): What is an anti-aging treatment? Experimental Gerontology 58; 14-18
  https://www.reddit.com/r/Futurology/comments/3fri9a/ask_aubrey_de_grey_anything
• Guevara-Aguirre, J; Balasubramanian, P; Guevara-Aguirre, M; Wei, M; Madia, F; Cheng, CW; Hwang, D; Martin-Montalvo, A et al. (2011): "Growth Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-Aging Signaling, Cancer, and Diabetes in Humans". Science Translational Medicine 3 (70): 70ra13. doi:10.1126/scitranslmed.3001845. PMC 3357623. PMID 21325617.

Hormone Receptor Deficiency Is Associated with a Major Reduction in Pro-
aging pill pushed as bona fide drug. Regulators asked to consider ageing as a treatable condition. Nature 522, 265-266

Human Mortality Database. University of California, Berkeley (USA), and Max Planck Institute for Demographic Research (Germany). Available at www.mortality.org (data downloaded on April 20th 2015).

• Planchet F (2006): Tables de mortalité d’expérience pour les portefeuilles de rentiers (Tables TGH 05 et TGF 05). Note méthodologique de l’Institut des Actuaires.

Do actuaries believe in longevity deceleration? Longevity 11, ISFA 2015